The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

UCLA investigators develop collection of sarcoma patient-derived organoids for personalized cancer treatments

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have developed the largest collection of sarcoma patient-derived organoids to date that can help improve the understanding of the disease and better identify therapies that are most likely to work for each individual patient. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Traditional pathological features used to classify aggressive prostate cancer—such as high-grade disease, cancer extending outside the prostate and cancer involving the seminal vesicles—after surgery do not predict who will benefit more from adding hormone therapy to postoperative radiation, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center. 
In Brief

UCLA researchers receive $3.9M NCI grant to boost the effectiveness of cancer immunotherapy

Cristina Puig-Saus, an associate professor of microbiology, immunology and molecular genetics and surgical oncology at the David Geffen School of Medicine at UCLA and an investigator at the UCLA Health Jonsson Comprehensive Cancer Center, and her research team have received a five-year, $3.9 million grant from NCI to develop drug-based strategies that could enhance cancer immunotherapy for patients with melanoma and potentially other types of cancer. 
Drugs & Targets

FDA approves Tecelra for pediatric synovial sarcoma

FDA granted full approval of Tecelra (afamitresgene autoleucel) and expanded its indication to include pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. 
In Brief

UCLA researchers awarded $3.2M NIH grant to develop AI tool for more personalized liver cancer treatment

Jason Chiang and Kyung Sung of the Department of Radiological Sciences at the David Geffen School of Medicine at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center have received a $3.2 million, five-year grant from NCI to develop an artificial intelligence-enhanced imaging platform designed to improve yttrium-90 (Y90) radioembolization planning for patients with liver cancer.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account